Cuba: The Cuban biopharmaceutical industry produces on a large scale the vaccine candidate Abdala against Covid-19, in order to ensure the necessary doses for its phase III clinical trial, BioCubaFarma announced today.
In its official Twitter account, the Business Group of the Biotechnology and Pharmaceutical Industries of the Caribbean country (BioCubaFarma), showed images of the bulb plant belonging to the AICA Laboratories where the Abdala production process takes place.
Likewise, it announced the visit to these facilities of the Vice President of BioCubaFarma, Eulogio Pimentel, together with directors of the Center for Genetic Engineering and Biotechnology (CIGB), leader of the project of that vaccine.
“During the tour it was found that the CIGB and AICA Laboratories production system constitutes a guarantee for the manufacture of this vaccine candidate,” a tweet says.